FDA

In a much-needed update to 2003 data on attention-deficit/hyperactivity disorder in the US, a new report has found that 15.5 million American adults have been diagnosed with the condition – and many have been let down by poor access to treatment.

A pioneering once-a-day pill that regenerates nerve cell connections damaged by ALS has been FDA-approved for ongoing clinical trials. The drug is now being given to those with ALS and could be a watershed moment in the treatment of the fatal disease.

A drug used to treat asthma has been shown to substantially reduce the risk of potentially life-threatening reactions in people aged one and older with multiple common food allergies, including peanuts, following accidental exposure.

The FDA has granted clearance to the first AI-powered medical device to assist physicians in detecting all 3 common skin cancers. Providing a more accurate way of identifying skin cancer will enable patients to access necessary treatment more quickly.

The FDA has approved the first cell-based gene therapies for treating sickle cell disease, one of which is the first approved therapy to utilize the CRISPR/Cas9 gene editing technology. It signals advancements in gene therapy and regenerative medicine.

The US has officially got a homegrown hero in the burgeoning global industry of effective weight-loss treatment, with the FDA approval of Lilly’s Zepbound. The company has revealed its cost, dosages, insurance subsidies and when it will be on shelves.

With an industry expected to be worth US$100 billion by 2030, a supply crisis, slow manufacturing processes, and a high price tag, it's no surprise the much-hyped class of injectable weight-loss drugs has become a prime target for counterfeit trade.

Adding weight to the large body of scientific evidence that has found phenylephrine is as useless as a placebo for nasal congestion, an advisory panel has declared common oral medications ineffective and urged for them to be removed from sale.

The US Food and Drug Administration recently fast-tracked its approval of brexpiprazole (Rexulti), an antipsychotic for treating agitation in dementia patients, when clinical studies demonstrated an increased risk of death and no meaningful benefit.

A debate has raged for decades as to whether a common artificial sweetener, aspartame, causes cancer. While the World Health Organization has now said it 'possibly' does, experts argue there's little evidence to support this and that it's still safe.

The first Alzheimer’s disease medication shown in trials to slow progression of the disease by 27% has been given full approval by the Food and Drug Administration, paving the way for its costly price tag to be covered by Medicare.

The FDA has approved a new drug for patients in the early-stages of Alzheimer's disease but growing concerns over its safety and real-world efficacy have led to division amongst researchers, with some suggesting it should not be authorized for wide use.